Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
Epilepsy is one of the most common serious chronic brain disorders of childhood. The causes
of epilepsy include :acquired brain damage, altered metabolic states, inborn brain
malformations, and genetic causes. At present, antiepileptic drugs (AEDs) are the first line
therapy for resistant epilepsy (RE) , and the second line is surgery , and vagus nerve
stimulation . Sodium valproate (SV) is a first line anti epileptic drug that can be applied
to various seizure types in children . SV has anticonvulsant activity through regulation of
neuronal pathways . It has a molecular structure similar to neurotransmitter γ aminobutyric
acid (GABA) resulting in GABA synergism , A serious adverse effect of the valproic acid (VPA)
: is its effect on liver function with resultant drug-induced hepatotoxicity, hyperammonemia
. Lamotrigine (LTG) is a second generation AED
. LTG belongs to the sodium channel blocking class of antiseizure medications (ASMs).
Lamortigine side effects include severe rash, fever, lymphadenopathy, hepatic dysfunction,
blood disorder,and disseminated intravascular coagulation and Stevens-Johnson syndrome (SJS)
. the aim : Evaluation of the efficacy and safety of adding lamotrigine to sodium valproate
in epileptic children not responding to SV alone for 6 months. Moreover, the investigators
will evaluate the effects of this addition ,appearance of side effects,laboratory evaluation
and EEG changes 50 epileptic patients receive SV for 6 months without complete remission for
participants, the investigators will add lamotrigine for 6 months.